Jan 6, 2025, 11:35
Biagio Ricciuti: TROPICS-03 trial – Sacituzumab Govitecan in 2L extensive stage SCLC
Biagio Ricciuti, Thoracic oncologist at the Dana-Farber Cancer Institute, shared a post on X:
“TROPICS-03 trial: Sacituzumab Govitecan in 2L extensive stage SCLC.
Ph II (N=43)
ORR 41.9%
– 35% platinum-resistant & 48% in platinum-sensitive)
PFS 4.4 and OS 13.6 months
Promising activity with however high rate of G3+ TRAEs (74.4%).”
Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 5, 2025, 05:59
Jun 5, 2025, 05:45
Jun 5, 2025, 05:05